Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.69 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | SQLE | Q14534 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838252 | 1.00 | NR1I2 (0.69) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL2834965 | 1.00 | NR1I2 (0.69) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL2833728 | 1.00 | NR1I2 (0.69) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL2833754 | 0.97 | NR1I2 (0.73) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL2832173 | 0.96 | NR1I2 (0.61) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL2835870 | 0.91 | KDM1A (0.58) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL4847430 | 0.88 | NR1I2 (0.53) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL18887568 | 0.88 | NR1I2 (0.53) | NR1I2LMNAPGRKDM1AFNTA | |
| SCHEMBL2837840 | 0.87 | NR1I2 (0.93) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL323577 | 0.87 | NR1I2 (0.93) | NR1I2LMNAPGRFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180320170-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2018-11-08 | — | — | US | disclosed |
| US-9944925-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. | 2018-04-17 | — | — | US | disclosed |
| EP-1848424-B1 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160186168-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20110065783-A1 | HYDROXYLATED NEBIVOLOL METABOLITES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-17 | — | — | US | disclosed |
| US-7838552-B2 | Compositions comprising nebivolol | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-23 | — | — | US | disclosed |
| US-20080161296-A1 | Compositions comprising nebivolol | DEY, INC. (F/K/A DEY LABORATORIES, INC.) | 2008-07-03 | — | — | US | disclosed |
| US-20070014734-A1 | Glucuronidated nebivolol metabolites | MYLAN INC. (F/K/A MYLAN LABORATORIES INC.) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161296-A1 | Compositions comprising nebivolol | ADRB1, ADRB3, ADRB2 | NR1I2 554/4885LMNA 185/4885PGR 3963/4885 |
| US-20070014734-A1 | Glucuronidated nebivolol metabolites | UGT1A4, UGT1A3, UGT1A1 | NR1I2 241/4885LMNA 1082/4885PGR 3024/4885 |
| US-20110065783-A1 | HYDROXYLATED NEBIVOLOL METABOLITES | EDNRB, EDNRA, ADRB1 | NR1I2 967/4885LMNA 862/4885PGR 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.